Our pipeline is built on small molecule, orally available therapies designed to bind to their targets with greater precision and affinity than other kinase inhibitors. By precisely targeting the cell signaling pathways that drive cancer growth and progression, we have selected each drug candidate in our pipeline for its potential to be a best-in-class therapy.
Repotrectinib (ROS1/TRK)1
Discovery
Preclinical
Early Stage Clinical Development
Late Stage Clinical Development
Regulatory Submission
TRIDENT-1: Advanced NSCLC (ROS1) And Solid Tumors (NTRK)
CARE: Pediatric Advanced Solid Tumors
TRIDENT-2: KRAS-Targeting Combination
Elzovantinib (MET)1
SHIELD-1: Advanced Solid Tumors
SHIELD-2: EGFR Combination
TPX-0046 (RET)2
SWORD-1: Advanced Solid Tumors
TPX-0131 (ALK)2
FORGE-1: Advanced NSCLC
Discovery Programs
KRAS G12D
p21 Activated Kinase
Multiple GTPase Oncology Targets
1Partnered with Zai Lab in Greater China; Turning Point retains worldwide rights outside of Greater China.
2Turning Point retains worldwide rights.
